Clinical Trial Update: Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity when the 9-valent HPV vaccine is coadministered with Moderna's mRNA-1273 COVID-19 vaccine. The study is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)
• Spikevax (mRNA-1273)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19) | Phase 3 | Status: COMPLETED | Results posted: 2025-07-17